A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

Trial Details

NCT ID
NCT05475925
Phase
PHASE1 / PHASE2
Sponsor
Dren Bio
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • DR-01
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Redwood City, California, United States|37.48522,-122.23635
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • ≥18 years of age.
  • Able to understand and comply with protocol-required study procedures and voluntarily sign a written informed consent document.
  • Sufficient key organ performance and coagulation.
  • Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at least one ovary, and is \<1 year postmenopausal) must agree …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →